Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis
For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
<p>For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.</p>